Omada Health Inc. Common Stock (OMDA)
Stock · NASDAQ · Health Care
$17.65as of 10/16/2026
Price chart
Active signals
OMDA Signal Track Record
How signals performed across all stocks →What OMDA's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 3 | -1.5% | 33% | September 18, 2026 |
| Bollinger Band BreakdownActive now | 3 | +17.3% | 67% | September 3, 2026 |
| Bollinger Band Breakout | 3 | +8.6% | 100% | June 25, 2026 |
| Any 20-session window (baseline) | +12.6% | 72% |
Computed by MarketWall from daily closing prices since March 24, 2026. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About OMDA
Omada Health, Inc., together with its subsidiary, Physera, Inc., provides a range of virtual care programs in the United States. The company offers cardiometabolic programs for prediabetes, diabetes, and hypertension; a physical therapy program to address musculoskeletal conditions; other support programs for members taking glucagon-like peptide-1 agonists in its cardiometabolic program; and weight management program…
- Sector
- Health Care
- Industry
- Medical/Nursing Services
- Employees
- 946
- Website
- www.omadahealth.com/
Fundamentals
- 1-day range
- $17.95$18.85
- Market cap
- $1.16B
- P/E (trailing)
- 265.49
- P/E (forward)
- 33.57
- EPS (trailing)
- $0.07
- Dividend yield
- —
- Beta
- 1.91
- Avg. volume
- 1.41M
How Omada Health Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 6, 2026 · via SEC EDGAR / Finnhub
Forecasts
12 analyst ratings
Omada Health Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- OMDAOmada Health Inc. Common Stock$17.63▼ 5.57%Market cap $1.16BP/E 265.49$10.28$26.92
- USPHU.S. Physical Therapy Inc. Common Stock$85.71▼ 0.31%Market cap $1.16BP/E 39.50$58.19$93.5
- LFMDPLifeMD Inc. 8.875% Series A Cumulative Perpetual Preferred Stock$22.18▲ 0.81%Market cap $1.12BP/E 589.89$2.36$6.53
- TDOCTeladoc Health Inc. Common Stock$5.67▼ 5.03%Market cap $1.21BP/E —$4.4$9.89
- PNTGThe Pennant Group Inc. Common Stock$41.87▼ 0.95%Market cap $1.36BP/E 46.02$22.26$42.74
- INNVInnovAge Holding Corp. Common Stock$8.85▼ 1.45%Market cap $1.49BP/E —$3.94$12.64
- AHCOAdaptHealth Corp. Common Stock$6.02▼ 5.79%Market cap $824.20MP/E —$5.21$13.43
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| OMDA Omada Health Inc. Common Stock | $1.16B | 265.49 | $17.63 | ▼ 5.57% | $10.28$26.92 |
| USPH U.S. Physical Therapy Inc. Common Stock | $1.16B | 39.50 | $85.71 | ▼ 0.31% | $58.19$93.5 |
| LFMDP LifeMD Inc. 8.875% Series A Cumulative Perpetual Preferred Stock | $1.12B | 589.89 | $22.18 | ▲ 0.81% | $2.36$6.53 |
| TDOC Teladoc Health Inc. Common Stock | $1.21B | — | $5.67 | ▼ 5.03% | $4.4$9.89 |
| PNTG The Pennant Group Inc. Common Stock | $1.36B | 46.02 | $41.87 | ▼ 0.95% | $22.26$42.74 |
| INNV InnovAge Holding Corp. Common Stock | $1.49B | — | $8.85 | ▼ 1.45% | $3.94$12.64 |
| AHCO AdaptHealth Corp. Common Stock | $824.20M | — | $6.02 | ▼ 5.79% | $5.21$13.43 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Transcript: Omada Health Q2 2026 Earnings Conference Callbenzinga · 10/12/2026
- Is Omada Health (OMDA) Cheap As Investors Question Its Long Term Targets?Yahoo · 10/9/2026
- Omada Health Shows Promising Growth But I Question The MoatSeekingAlpha · 10/9/2026
- Omada Health President Wei-Li Shao Sells 9,418 Shares for $236,000Yahoo · 9/23/2026
- Barclays Maintains Overweight on Omada Health, Raises Price Target to $27Benzinga · 9/11/2026
Insider Activity
Insider Actions →- Julie D. Klapstein · October 5, 2026 · Grant549
- Jonathan D. Root · October 5, 2026 · Grant694
- Jeryl L. Hilleman · October 5, 2026 · Grant1.2K
- Trevor Fetter · October 5, 2026 · Grant751
- Sean P. Duffy · October 1, 2026 · Option Exercise4.3K @ $8.28
- Sean P. Duffy · October 1, 2026 · Option Exercise12.9K @ $5.82
- Sean P. Duffy · October 1, 2026 · Sale4.3K @ $20.9
- Sean P. Duffy · October 1, 2026 · Sale12.9K @ $20.61
- Sean P. Duffy · September 10, 2026 · Sale13.6K @ $21.8
- Steven L. Cook · September 10, 2026 · Sale600 @ $22.52
- Steven L. Cook · September 10, 2026 · Sale6.2K @ $21.8
- Wei-Li Shao · September 10, 2026 · Sale400 @ $22.53
- Sean P. Duffy · September 10, 2026 · Sale1.4K @ $22.59
- Wei-Li Shao · September 10, 2026 · Sale3.6K @ $21.78
- Craig Gracey · September 9, 2026 · Sale644 @ $21.73
Institutional Ownership
March 31, 2026
- Total shares held
- 48.67M
- Total value held
- $554.22M
- Institutional holders
- 135
- Unknown5.89M
- Unknown5.21M
- Unknown3.44M
- Unknown3.29M
- Unknown2.53M
- Unknown2.46M
- Unknown2.31M
- Unknown1.90M
- Unknown1.81M
- Unknown1.71M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Omada Health Sets Q3 2026 Earnings Call, Investors Question Valuation
Omada Health will report its third quarter 2026 results on November 5 and host a conference call. Recent commentary highlights the company’s growth but raises concerns about its competitive moat and long‑term price targets. Analysts note a high trailing P/E of 260.2 and a wide target range of $22.00 to $35.00. The upcoming call may clarify how the firm plans to address these valuation questions.
Omada Health Sets Q3 2026 Earnings Call, Investors Question Valuation. Omada Health will report its third quarter 2026 results on November 5 and host a conference call. Recent commentary highlights the company’s growth but raises concerns about its competitive moat and long‑term price targets. Analysts note a high trailing P/E of 260.2 and a wide target range of $22.00 to $35.00. The upcoming call may clarify how the firm plans to address these valuation questions.